Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.56 |
| ▸ | GPR3 | P46089 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SCN4A | P35499 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1241806 | 0.89 | FFAR4 (0.55) | FFAR4GPR3NPC1RAB9ASCN5A | |
| SCHEMBL710315 | 0.83 | NR4A1 (0.54) | FFAR4RAB9AGAASMN1; SMN2AR | |
| SCHEMBL8146457 | 0.82 | NR4A1 (0.52) | FFAR4RAB9AGAALMNACYP3A4 | |
| SCHEMBL29546263 | 0.81 | NR4A1 (0.56) | FFAR4GPR3NPC1RAB9ASCN5A | |
| SCHEMBL442684 | 0.81 | NR4A1 (0.56) | FFAR4GPR3NPC1RAB9ASCN5A | |
| SCHEMBL29463893 | 0.80 | GPR3 (0.44) | FFAR4GPR3NPC1RAB9ASCN5A | |
| SCHEMBL77088 | 0.80 | FFAR4 (0.56) | FFAR4RAB9AGAACYP3A4BLM | |
| SCHEMBL11832556 | 0.80 | GPR3 (0.44) | FFAR4GPR3NPC1RAB9ASCN5A | |
| SCHEMBL29961263 | 0.80 | FFAR4 (0.56) | FFAR4RAB9AGAACYP3A4BLM | |
| Hydrochloric Acid SCHEMBL9526864 | 0.79 | NR4A1 (0.54) | FFAR4GPR3NPC1RAB9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010081149-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLAXOSMITHKLINE LLC (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-1326845-B1 | N-ALKOXYALKYL-SUBSTITUTED BENZIMIDAZOLES AND THE USE THEREOF AS AN AGENT AGAINST PARASITIC PROTOZOANS | BAYER HEALTHCARE AG (DE) | 2005-12-14 | — | — | EP | disclosed |
| US-20040044055-A1 | N-alkoxlyalkyl-substituted benzimidazoles and the use thereof as an agent against parastic protozoans | BAYER AKTIENGESELLSCHAFT (DE) | 2004-03-04 | — | — | US | disclosed |
| EP-1326845-A1 | N-ALKOXYALKYL-SUBSTITUTED BENZIMIDAZOLES AND THE USE THEREOF AS AN AGENT AGAINST PARASITIC PROTOZOANS | Bayer Aktiengesellschaft (DE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002030909-A1 | N-ALKOXYALKYL-SUBSTITUTED BENZIMIDAZOLES AND THE USE THEREOF AS AN AGENT AGAINST PARASITIC PROTOZOANS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044055-A1 | N-alkoxlyalkyl-substituted benzimidazoles and the use thereof as an agent against parastic protozoans | PIGO, EPX, PIGK | FFAR4 3110/4885GPR3 772/4885NPC1 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.